Loading...
Market
Belantamab Mafodotin Revenue Rank Among GSK Oncology Drugs in 2025
4
Resolution / Starting Odds
Top 1 • 25%
Top 2 • 25%
Top 3 • 25%
Top 4+ • 25%
GSK financial reports and earnings announcements
Story
GSK's Belantamab Mafodotin Shows Promise in Myeloma Trials with PFS HR=0.52 and OS HR=0.77
Jun 2, 2024, 12:25 PM
In recent clinical trials presented at the ASCO 2024 conference, GSK's blood cancer drug belantamab mafodotin has shown promising results in treating relapsed or refractory myeloma. The DREAMM-7 trial revealed that patients treated with a regimen including belantamab mafodotin had a median progression-free survival (PFS) of about 3 years, compared to approximately 13 months with a regimen including an anti-CD38 antibody. Additionally, the DREAMM-8 trial reported a 1-year PFS that was 20 percentage points higher for patients treated with belantamab mafodotin, pomalidomide, and dexamethasone compared to those treated with bortezomib, pomalidomide, and dexamethasone. The PFS HR was 0.52, and the immature OS HR was 0.77. The data suggests a potential comeback for belantamab mafodotin, which had previously been pulled from the market, and experts believe it 'should return' to the US market.
View original story
Similar markets
Below £500 million • 25%
£500 million to £1 billion • 25%
£1 billion to £2 billion • 25%
Above £2 billion • 25%
Oncology • 25%
Biopharmaceuticals • 25%
Rare diseases • 25%
Other • 25%
Below $1 billion • 33%
$1 billion - $5 billion • 33%
Above $5 billion • 34%
Less than $1 billion • 33%
$1 billion to $5 billion • 33%
More than $5 billion • 33%
Increase • 33%
No significant change • 33%
Decrease • 33%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Less than $500 million • 33%
$500 million to $1 billion • 33%
Greater than $1 billion • 34%
